Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets: 2012-2025

Historic Other Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $3.4 million.

  • Enanta Pharmaceuticals' Other Non-Current Assets changed negligibly% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2025, which is negligibly% changed negligibly from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $3.4 million for Q3 2025, which was down 0.00% from $3.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $4.0 million during Q2 2022, with a 5-year trough of $608,000 in Q1 2021.
  • For the 3-year period, Enanta Pharmaceuticals' Other Non-Current Assets averaged around $3.6 million, with its median value being $3.4 million (2025).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first spiked by 552.63% in 2022, then decreased by 15.32% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Other Non-Current Assets stood at $608,000 in 2021, then spiked by 552.63% to $4.0 million in 2022, then remained steady at $4.0 million in 2023, then decreased by 15.32% to $3.4 million in 2024, then remained steady at $3.4 million in 2025.
  • Its Other Non-Current Assets stands at $3.4 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.4 million for Q1 2025.